Relmada (RLMD) Q1 2026 earnings review
Survival Secured, Execution Phase Begins
Relmada has transformed from a distressed biotech into a well-capitalized execution story. A massive $160 million PIPE financing in Q1 2026 pushed the cash balance to $234 million, entirely removing financing overhang and securing runway through 2029. Meanwhile, NDV-01 continues to deliver pristine clinical data, holding an 80% 12-month complete response rate in hard-to-treat BCG-unresponsive bladder cancer. The narrative is no longer about survival—it's about successfully launching the Phase 3 RESCUE program in mid-2026. However, this survival came at an immense cost to legacy shareholders: outstanding shares more than tripled over the last year.
🐂 Bull Case
With $234 million in the bank, Relmada has enough cash to fund operations through 2029. This completely de-risks the completion of the Phase 3 RESCUE program for NDV-01.
12-month data validation (76% CR in high-risk NMIBC; 80% in BCG-unresponsive) solidifies NDV-01's best-in-class potential ahead of the Phase 3 launch.
🐻 Bear Case
The company issued an enormous amount of equity to survive, expanding shares outstanding from 33.2M in Q1 2025 to 104.9M today, severely capping per-share upside for legacy holders.
With funding secured, the pressure is entirely on management to seamlessly execute two Phase 3 NDV-01 cohorts and a Phase 2 Sepranolone study concurrently starting in mid-2026.
⚖️ Verdict: 🟢
Bullish. The balance sheet turnaround is spectacular. While the historical dilution is painful, looking forward, the company is now a fully-funded, pure-play clinical execution vehicle with highly competitive Phase 2 oncology data.
Key Themes
Unprecedented Balance Sheet Fortification
Relmada eliminated its biggest headwind: capital risk. The $160 million PIPE financing in Q1, following a $94 million offering in late 2025, catapulted the cash balance to $234 million. Management explicitly guided this will fund operations through 2029, comfortably covering the entirety of the NDV-01 Phase 3 RESCUE program.
The EPS Improvement is a Mathematical Illusion
On paper, the Q1 2026 EPS of -$0.22 looks like a vast improvement over the -$0.58 reported in Q1 2025. This contradicts the underlying financial reality. The net loss actually worsened to $19.1 million from $17.6 million. The 'improved' EPS is strictly the mathematical result of severe dilution, with weighted average shares jumping from 30.4 million to 86.6 million year-over-year. Investors must ignore the per-share metrics and focus on absolute cash burn.
NDV-01 Efficacy Data Validates 'Best-in-Class' Claim
The 12-month Phase 2 data for NDV-01 continues to hold up remarkably well. The treatment demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk NMIBC. More importantly, in the highly refractory BCG-unresponsive subpopulation, it showed a 94% anytime CR and an 80% 12-month CR. Crucially, zero patients progressed to muscle-invasive disease or required radical cystectomy.
Disruptive Delivery Technology
NDV-01's formulation—a sustained-release gemcitabine and docetaxel (Gem/Doce)—is as critical as its efficacy. Designed to form a soft intravesical matrix, it controls drug release over 10 days. This allows for streamlined, in-office administration in under 5 minutes without anesthesia, a stark contrast to the logistical hurdles of standard sequential Gem/Doce administration.
Dual-Track Phase 3 Strategy Expands TAM
FDA alignment on the RESCUE program allows Relmada to pursue two distinct markets simultaneously. Pathway 1 targets the massive intermediate-risk NMIBC adjuvant setting (~75,000 U.S. patients/year) via a randomized trial. Pathway 2 targets 2L BCG-unresponsive disease (~5,000 U.S. patients) via a single-arm trial, which offers a potentially rapid route to initial commercialization.
G&A Expenses Spike Ahead of Trial Launches
While R&D costs predictably fell to $8.1M as old trials wound down, G&A expense unexpectedly surged 81% YoY to $11.4 million in Q1 2026. Management attributed this to increased compensation costs. As the Phase 3 trials commence in mid-2026, R&D will re-accelerate; if G&A remains at this elevated baseline, total operating cash burn could climb faster than anticipated.
Congested NMIBC Competitive Landscape
Relmada is entering a highly competitive environment. The NMIBC space has seen recent approvals (e.g., Adstiladrin, Anktiva) and features advanced trials from competitors like CG Oncology. Relmada's clinical trial enrollment speed and eventual commercial uptake will heavily depend on convincing community urologists to adopt its specific in-office matrix formulation.
Other KPIs
Stable compared to -$18.1 million a year ago, but poised to accelerate negatively. Q1 burn reflects a lull between the wind-down of legacy CNS programs and the imminent mid-2026 initiation of the massive NDV-01 Phase 3 program.
Accelerating significantly from $6.3 million in 25Q1. This 81% YoY increase was primarily driven by compensation costs, indicating the company is heavily scaling corporate infrastructure ahead of its pivotal phase.
Guidance
Accelerating timeline security. Thanks to the $150M net PIPE proceeds, management officially extended runway guidance to 2029, a major upgrade from the 'into 2028' guidance provided just two quarters ago.
Accelerating operational momentum. The company reaffirmed strict mid-2026 targets for filing the NDV-01 IND, launching the Phase 3 RESCUE program, and initiating the Sepranolone Phase 2 trial.
Management expects to release initial 3-month data from the 2L BCG-unresponsive cohort of the RESCUE study by the end of 2026, establishing the next major binary catalyst for the stock.
Key Questions
G&A Expense Baseline
G&A expenses jumped 81% YoY to $11.4 million this quarter due to compensation. How much of this is a permanent structural increase versus one-time bonuses tied to the successful PIPE financing?
Phase 3 Enrollment Mechanics
Given the highly congested landscape of NMIBC trials right now, what specific strategies and site-activation metrics give you confidence in rapid enrollment for the RESCUE program?
Capital Allocation Strategy
With an outsized $234 million cash pile extending runway through 2029, are you actively evaluating further in-licensing opportunities, or is the strategic mandate strictly 100% focus on NDV-01 and Sepranolone?